^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Cabazitaxel versus enzalutamide/abiraterone in CARD eligible mCRPC patients with or without germline HRR defects.
Published date:
05/13/2020
Excerpt:
In gHRR carriers CBZ was not superior to ARSi in terms of rPFS (2.5 vs. 3.0 m, p=0.8), cPFS (2.5 vs. 2.4 m, p=0.8) and OS (4.5 vs. 3.7, p=0.8)....However, the outcomes in gHRR carriers are poor with either CBZ or ARSi supporting the need of novel therapies in this setting.
DOI:
10.1200/JCO.2020.38.15_suppl.5554
Trial ID:
